Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 14;39(10):145.
doi: 10.1007/s12032-022-01739-3.

Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice

Giandomenico Roviello  1 , Martina Catalano  2 , Carlotta Ottanelli  2 , Roberta Giorgione  2 , Virginia Rossi  3 , Elisabetta Gambale  3 , Chiara Casadei  4 , Ugo De Giorgi  4 , Lorenzo Antonuzzo  3   5
Affiliations
Review

Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice

Giandomenico Roviello et al. Med Oncol. .

Abstract

The treatment landscape for metastatic castration-resistant prostate cancer has evolved extremely in recent years and several drug classes are now available. Nonetheless, the lack of validated predictive biomarkers makes therapeutic choice and the best sequential approach difficult. The location of the metastatic site could be a valid criterion for choosing among the treatment options available. Although bone remains the most frequent metastatic site and a possible target for many drugs, recent data suggest a profound shift in the disease spectrum with visceral metastases increasing incidence. This review describes the presently available and ongoing therapies for patients with CRPC and bone metastases, focusing on the role of bone metastases as a possible driver for selecting therapies in these patients.

Keywords: 177Lu-PSMA-617; Androgen receptor signaling inhibitors; Bone metastases; Chemotherapy; Metastatic castration-resistant prostate cancer; PARP inhibitors; Sipuleucel-T; radium223.

PubMed Disclaimer

References

    1. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63–89. - PubMed - PMC - DOI
    1. McCain J. Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: New and emerging treatment options. Vol. 39, P and T. Medi Media USA Inc; 2014. p. 130.
    1. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. FDA [Internet] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro... . Accessed 16 Oct 2021.
    1. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103. - PubMed - PMC - DOI
    1. Zustovich F, Fabiani F. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. Vol. 91, Critical Reviews in Oncology/Hematology. Elsevier Ireland Ltd; 2014; 197–209.

LinkOut - more resources